시장보고서
상품코드
1811036

세계의 뇌전증 지속증 시장 보고서(2025년)

Status Epilepticus Global Market Report 2025

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

세계의 뇌전증 지속증 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년까지 연평균 복합 성장률(CAGR) 5.7%로 확대되어 16억 8,000만 달러로 성장할 것으로 예상됩니다. 예측기간 동안 성장이 예상되는 요인으로는 외상성 뇌손상의 증례 수 증가, 세계 인구의 고령화, 즉효성 있는 치료에 대한 수요 증가, 원격신경학 서비스 확대, 상환제도 개선 등이 있습니다. 예측되는 시장 동향으로는 침습성이 낮은 진단 방법으로의 이행, 웨어러블 발작 모니터링 기술의 이용 확대, 발작 치료에서 디지털 의료 기록의 통합 확대, 진단에서 인공지능(AI)의 이용, 혁신적인 항발작약 개발 등을 들 수 있습니다.

신경질환 증가는 향후 뇌전증 지속증 시장의 확대를 촉진할 것으로 예측됩니다. 이 질병은 중추 신경계와 말초 신경계에 영향을 미치며 인지 장애와 운동 기능 장애와 같은 다양한 장애를 초래합니다. 세계 인구의 고령화에 따라 뇌의 가소성 저하, 신경 세포 활동의 장애, 산화 스트레스 증가에 의해 이러한 질환의 유병률이 증가합니다. 이러한 유병률 증가는 신경세포 기능을 불안정화시킴으로써 발작이 장기화할 위험을 높여줍니다. 예를 들어 영국의 공중보건기구인 국민보건서비스(NHS)가 2024년 7월에 보고한 바에 따르면 2024년 6월 30일 현재 48만 7,432명의 치매 환자가 있으며 2024년 5월 31일에 비해 3,155명 증가하고 있습니다. 이러한 신경학적 사례 증가는 진단 및 관리 전략의 개선의 필요성을 강조하고 시장 성장에 기여합니다.

뇌전증 지속증 시장의 주요 기업은 AI를 탑재한 진단 툴을 포함한 기술적으로 첨단 솔루션의 혁신에 주력하고 있으며, 발작을 보다 정확하게 검출하고 신경내과에서의 케어의 효율을 높이고 있습니다. 이러한 AI 구동 플랫폼은 실시간 뇌 활동 모니터링을 활용하여 발작을 신속하게 파악하고 특히 긴급 환경에서 신속한 임상 판단을 지원합니다. 예를 들어 미국에 본사를 둔 Ceribell Inc.는 2023년 10월 Ceribell의 EEG 시스템과 통합하여 발작 활동을 실시간으로 지속적으로 분석하는 새로운 소프트웨어인 ClarityPro AI를 발표했습니다. 이 혁신은 신경학적 고통을 가진 환자에게 적시 개입을 제공하고 치료 결과를 개선하기 위해 건강 관리 팀을 지원합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

  • 세계 뇌전증 지속증 시장 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
  • 최종 이용 산업의 분석
  • 세계 뇌전증 지속증 시장 : 성장률 분석
  • 세계 뇌전증 지속증 시장 실적 : 규모와 성장, 2019-2024년
  • 세계 뇌전증 지속증 시장 예측 : 규모와 성장, 2024-2029년, 2034년
  • 세계 뇌전증 지속증 시장 : 총 시장 규모(TAM)

제6장 시장 세분화

  • 세계의 뇌전증 지속증 시장 : 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
  • 경련성 뇌전증 지속증
  • 비경련성 뇌전증 지속증
  • 세계의 뇌전증 지속증 시장 : 약별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
  • 제1세대
  • 제2세대
  • 제3세대
  • 신경 조절 장치
  • 세계의 뇌전증 지속증 시장 : 약제별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
  • 가낙솔론
  • 디아제팜
  • 페노바르비탈
  • 페니토인 및 포스페니토인
  • 밸프로에이트
  • 기타
  • 세계의 뇌전증 지속증 시장 : 유통 채널별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
  • 병원 약국
  • 온라인 약국
  • 소매 약국
  • 세계의 뇌전증 지속증 시장 : 경련성 뇌전증 지속증별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
  • 일반 경련 뇌전증 지속증(GCSE)
  • 국소 운동 뇌전증 지속증
  • 근간대 뇌전증 지속증
  • 강직성 뇌전증 지속증
  • 세계의 뇌전증 지속증 시장 : 비경련성 뇌전증 지속증별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
  • 소발작 뇌전증 지속증
  • 복잡 부분적 뇌전증 지속증
  • 뇌파 뇌전증 지속증
  • 경미 뇌전증 지속증

제7장 지역별/국가별 분석

  • 세계의 뇌전증 지속증 시장 : 지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
  • 세계의 뇌전증 지속증 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

  • 뇌전증 지속증 시장 : 경쟁 구도
  • 뇌전증 지속증 시장 : 기업 프로파일
    • Pfizer Inc.
    • Novartis AG
    • Takeda Pharmaceutical Company Limited
    • Bausch Health Companies Inc.
    • Eisai Co. Ltd.

제31장 기타 주요 기업 및 혁신 기업

  • Dr. Reddy's Laboratories
  • Hikma Pharmaceuticals plc
  • Mylan NV
  • Lupin Pharmaceuticals Limited
  • Torrent Pharmaceuticals Ltd.
  • Neuraxpharm
  • Ligand Pharmaceuticals Incorporated
  • Rafa Laboratories Ltd.
  • Esteive Therapeutics
  • Nobelpharma Co. Ltd.
  • Neurelis Inc.
  • SAGE Therapeutics
  • Immedica Pharma AB
  • Sedor Pharmaceuticals
  • Crossject SA

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

  • 뇌전증 지속증 시장(2029년) : 새로운 기회를 제공하는 국가
  • 뇌전증 지속증 시장(2029년) : 새로운 기회를 제공하는 부문
  • 뇌전증 지속증 시장(2029년) : 성장 전략
    • 시장 동향에 의한 전략
    • 경쟁 전략

제36장 부록

JHS 25.09.24

Status epilepticus represents a medical emergency defined by a seizure that continues for more than five minutes or recurrent seizures where the individual does not regain full consciousness between episodes. If not treated swiftly, it can lead to permanent neurological damage or even be fatal.

There are two primary types of status epilepticus: convulsive status epilepticus and non-convulsive status epilepticus. Convulsive status epilepticus is a critical and extended seizure episode marked by ongoing or repeated convulsions, commonly involving rhythmic muscle movements and unconsciousness. Management includes the use of medications such as first-generation, second-generation, and third-generation drugs, as well as neuromodulation devices. Drugs administered for treatment include ganaxolone, diazepam, phenobarbital, phenytoin and fosphenytoin, valproate, among others. These treatments are distributed through several channels, including hospital pharmacies, online pharmacies, and retail pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The status epilepticus market research report is one of a series of new reports from The Business Research Company that provides status epilepticus market statistics, including the status epilepticus industry's global market size, regional shares, competitors with an status epilepticus market share, detailed status epilepticus market segments, market trends and opportunities, and any further data you may need to thrive in the status epilepticus industry. This status epilepticus market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The status epilepticus market size has grown strongly in recent years. It will grow from $1.27 billion in 2024 to $1.34 billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The expansion seen in the historic period is largely due to a rise in epilepsy cases, heightened awareness of neurological emergencies, increased utilization of benzodiazepines, more admissions to intensive care units (ICUs), and an overall surge in healthcare expenditure.

The status epilepticus market size is expected to see strong growth in the next few years. It will grow to $1.68 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. Anticipated growth during the forecast period can be attributed to factors such as a growing number of traumatic brain injury cases, an aging global population, greater demand for fast-acting therapeutics, the expansion of tele-neurology services, and better reimbursement schemes. Forecasted market trends include a move toward less invasive diagnostic methods, growing use of wearable seizure monitoring technology, wider integration of digital health records in seizure care, use of artificial intelligence (AI) in diagnostics, and the development of innovative anti-seizure medications.

The rise in neurological disorders is anticipated to drive the expansion of the status epilepticus market in the future. These disorders affect the central and peripheral nervous systems, resulting in various impairments such as cognitive and motor dysfunctions. As the global population ages, the prevalence of such conditions increases due to reduced brain plasticity, impaired neuronal activity, and higher oxidative stress. This growing prevalence elevates the risk of prolonged seizures by destabilizing neuronal functions. For example, as reported in July 2024 by the National Health Service (NHS), a UK-based public health provider, there were 487,432 diagnosed dementia patients as of June 30, 2024 - an increase of 3,155 cases compared to May 31, 2024. This rise in neurological cases underscores the need for improved diagnostic and management strategies, contributing to the market's growth.

Leading firms in the status epilepticus market are concentrating on innovating technologically advanced solutions, including AI-powered diagnostic tools, to better detect seizures and enhance care efficiency in neurology. These AI-driven platforms utilize real-time brain activity monitoring to identify seizures quickly and assist in making faster clinical decisions, particularly in emergency settings. For instance, in October 2023, U.S.-based Ceribell Inc. introduced ClarityPro AI, a new software that integrates with Ceribell's EEG systems to continuously analyze seizure activity in real time. This innovation supports healthcare teams in providing timely intervention and improving treatment outcomes for patients in neurological distress.

In February 2025, Immedica Pharma AB, a pharmaceutical company based in Sweden, acquired Marinus Pharmaceuticals Inc. to bolster its central nervous system (CNS) product lineup. This strategic acquisition allowed Immedica to gain access to ganaxolone, an essential therapy used in treating rare seizure-related disorders such as CDKL5 deficiency and status epilepticus. Marinus Pharmaceuticals Inc. is a U.S.-based biopharmaceutical company recognized for its work in developing ganaxolone to manage refractory status epilepticus.

Major players in the status epilepticus market are Pfizer Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Eisai Co. Ltd., Dr. Reddy's Laboratories, Hikma Pharmaceuticals plc, Mylan N.V., Lupin Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd., Neuraxpharm, Ligand Pharmaceuticals Incorporated, Rafa Laboratories Ltd., Aquestive Therapeutics, Nobelpharma Co. Ltd., Neurelis Inc., SAGE Therapeutics, Immedica Pharma AB, Sedor Pharmaceuticals, and Crossject SA.

North America was the largest region in the status epilepticus market in 2024. The regions covered in status epilepticus report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the status epilepticus market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The status epilepticus market consists of revenues earned by entities by providing services such as emergency medical interventions, critical care management, diagnostic imaging, and neurocritical care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The status epilepticus market also includes sales of benzodiazepines, antiepileptic drugs, general anesthetics, infusion pumps, and emergency medical kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Status Epilepticus Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on status epilepticus market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for status epilepticus ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The status epilepticus market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Convulsive Status Epileptics; Non-Convulsive Status Epileptics
  • 2) By Medication: First Generation; Second Generation; Third Generation; Neuromodulation Devices
  • 3) By Drug: Ganaxolone; Diazepam; Phenobarbital; Phenytoin And Fosphenytoin; Valproate; Other Drugs
  • 4) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
  • Subsegments:
  • 1) By Convulsive Status Epilepticus: Generalized Tonic-Clonic Status Epilepticus (GTCS SE); Focal Onset With Bilateral Tonic-Clonic Generalization; Myoclonic Status Epilepticus
  • 2) By Non-Convulsive Status Epilepticus (NCSE): Absence Status Epilepticus; Complex Partial Status Epilepticus; Subtle Status Epilepticus
  • Companies Mentioned: Pfizer Inc.; Novartis AG; Takeda Pharmaceutical Company Limited; Bausch Health Companies Inc.; Eisai Co. Ltd.; Dr. Reddy's Laboratories; Hikma Pharmaceuticals plc; Mylan N.V.; Lupin Pharmaceuticals Limited; Torrent Pharmaceuticals Ltd.; Neuraxpharm; Ligand Pharmaceuticals Incorporated; Rafa Laboratories Ltd.; Aquestive Therapeutics; Nobelpharma Co. Ltd.; Neurelis Inc.; SAGE Therapeutics; Immedica Pharma AB; Sedor Pharmaceuticals; Crossject SA.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Status Epilepticus Market Characteristics

3. Status Epilepticus Market Trends And Strategies

4. Status Epilepticus Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Status Epilepticus Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Status Epilepticus PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Status Epilepticus Market Growth Rate Analysis
  • 5.4. Global Status Epilepticus Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Status Epilepticus Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Status Epilepticus Total Addressable Market (TAM)

6. Status Epilepticus Market Segmentation

  • 6.1. Global Status Epilepticus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Convulsive Status Epileptics
  • Non-Convulsive Status Epileptics
  • 6.2. Global Status Epilepticus Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • First Generation
  • Second Generation
  • Third Generation
  • Neuromodulation Devices
  • 6.3. Global Status Epilepticus Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Ganaxolone
  • Diazepam
  • Phenobarbital
  • Phenytoin And Fosphenytoin
  • Valproate
  • Other Drugs
  • 6.4. Global Status Epilepticus Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • 6.5. Global Status Epilepticus Market, Sub-Segmentation Of Convulsive Status Epilepticus, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Generalized Convulsive Status Epilepticus (GCSE)
  • Focal Motor Status Epilepticus
  • Myoclonic Status Epilepticus
  • Tonic Status Epilepticus
  • 6.6. Global Status Epilepticus Market, Sub-Segmentation Of Non-Convulsive Status Epilepticus, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Absence Status Epilepticus
  • Complex Partial Status Epilepticus
  • Electrographic Status Epilepticus
  • Subtle Status Epilepticus

7. Status Epilepticus Market Regional And Country Analysis

  • 7.1. Global Status Epilepticus Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Status Epilepticus Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Status Epilepticus Market

  • 8.1. Asia-Pacific Status Epilepticus Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Status Epilepticus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Status Epilepticus Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Status Epilepticus Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Status Epilepticus Market

  • 9.1. China Status Epilepticus Market Overview
  • 9.2. China Status Epilepticus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Status Epilepticus Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Status Epilepticus Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Status Epilepticus Market

  • 10.1. India Status Epilepticus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Status Epilepticus Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Status Epilepticus Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Status Epilepticus Market

  • 11.1. Japan Status Epilepticus Market Overview
  • 11.2. Japan Status Epilepticus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Status Epilepticus Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Status Epilepticus Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Status Epilepticus Market

  • 12.1. Australia Status Epilepticus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Status Epilepticus Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Status Epilepticus Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Status Epilepticus Market

  • 13.1. Indonesia Status Epilepticus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Status Epilepticus Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Status Epilepticus Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Status Epilepticus Market

  • 14.1. South Korea Status Epilepticus Market Overview
  • 14.2. South Korea Status Epilepticus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Status Epilepticus Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Status Epilepticus Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Status Epilepticus Market

  • 15.1. Western Europe Status Epilepticus Market Overview
  • 15.2. Western Europe Status Epilepticus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Status Epilepticus Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Status Epilepticus Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Status Epilepticus Market

  • 16.1. UK Status Epilepticus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Status Epilepticus Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Status Epilepticus Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Status Epilepticus Market

  • 17.1. Germany Status Epilepticus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Status Epilepticus Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Status Epilepticus Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Status Epilepticus Market

  • 18.1. France Status Epilepticus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Status Epilepticus Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Status Epilepticus Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Status Epilepticus Market

  • 19.1. Italy Status Epilepticus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Status Epilepticus Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Status Epilepticus Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Status Epilepticus Market

  • 20.1. Spain Status Epilepticus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Status Epilepticus Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Status Epilepticus Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Status Epilepticus Market

  • 21.1. Eastern Europe Status Epilepticus Market Overview
  • 21.2. Eastern Europe Status Epilepticus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Status Epilepticus Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Status Epilepticus Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Status Epilepticus Market

  • 22.1. Russia Status Epilepticus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Status Epilepticus Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Status Epilepticus Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Status Epilepticus Market

  • 23.1. North America Status Epilepticus Market Overview
  • 23.2. North America Status Epilepticus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Status Epilepticus Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Status Epilepticus Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Status Epilepticus Market

  • 24.1. USA Status Epilepticus Market Overview
  • 24.2. USA Status Epilepticus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Status Epilepticus Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Status Epilepticus Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Status Epilepticus Market

  • 25.1. Canada Status Epilepticus Market Overview
  • 25.2. Canada Status Epilepticus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Status Epilepticus Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Status Epilepticus Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Status Epilepticus Market

  • 26.1. South America Status Epilepticus Market Overview
  • 26.2. South America Status Epilepticus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Status Epilepticus Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Status Epilepticus Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Status Epilepticus Market

  • 27.1. Brazil Status Epilepticus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Status Epilepticus Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Status Epilepticus Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Status Epilepticus Market

  • 28.1. Middle East Status Epilepticus Market Overview
  • 28.2. Middle East Status Epilepticus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Status Epilepticus Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Status Epilepticus Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Status Epilepticus Market

  • 29.1. Africa Status Epilepticus Market Overview
  • 29.2. Africa Status Epilepticus Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Status Epilepticus Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Status Epilepticus Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Status Epilepticus Market Competitive Landscape And Company Profiles

  • 30.1. Status Epilepticus Market Competitive Landscape
  • 30.2. Status Epilepticus Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Bausch Health Companies Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Eisai Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Status Epilepticus Market Other Major And Innovative Companies

  • 31.1. Dr. Reddy's Laboratories
  • 31.2. Hikma Pharmaceuticals plc
  • 31.3. Mylan N.V.
  • 31.4. Lupin Pharmaceuticals Limited
  • 31.5. Torrent Pharmaceuticals Ltd.
  • 31.6. Neuraxpharm
  • 31.7. Ligand Pharmaceuticals Incorporated
  • 31.8. Rafa Laboratories Ltd.
  • 31.9. Aquestive Therapeutics
  • 31.10. Nobelpharma Co. Ltd.
  • 31.11. Neurelis Inc.
  • 31.12. SAGE Therapeutics
  • 31.13. Immedica Pharma AB
  • 31.14. Sedor Pharmaceuticals
  • 31.15. Crossject SA

32. Global Status Epilepticus Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Status Epilepticus Market

34. Recent Developments In The Status Epilepticus Market

35. Status Epilepticus Market High Potential Countries, Segments and Strategies

  • 35.1 Status Epilepticus Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Status Epilepticus Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Status Epilepticus Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제